Abstract

We describe a patient with a rare combination of acromegaly and primary aldosteronism. A 37 year-old female patient was diagnosed with acromegaly on the basis of typical clinical, hormonal and image characteristics. She presented also with one of the most common co-morbidities - arterial hypertension. The patient has been regularly followed-up and after three surgical interventions, irradiation and adjuvant treatment with a dopamine agonist, acromegaly was finally controlled in 2008 (20 years after diagnosis). Arterial hypertension however, remained a therapeutic problem even after prescription of four antihypertensive drugs. She had normal biochemical parameters, except for low potassium levels 3.2 (3.5-5.6) mmol/l. This raised the suspicion of primary hyperaldosteronism, confirmed by a high aldosterone to plasma rennin activity ratio, high aldosterone level after a Captopril challenge test and visualization of a 35 mm left adrenal nodule on a CT scan. After an operation, the patient recovered from hypokalemia and antihypertensive therapy was reduced to a small dose of a Ca blocker. Co-morbid arterial hypertension is common in acromegaly, though it is rare for this to be caused by Conn's adenoma. The association of Conn's adenoma with acromegaly has been interpreted in two lines: as a component of multiple endocrine neoplasia type (MEN1) syndrome or as a direct mitogenic effect of hyperactivated GH-IGF1 axis.

Highlights

  • In the literature several patients with primary aldosteronism (PA) associated with endocrine and non-endocrine tumors have been reported[1,2,3]

  • Aldosterone-producing adenomas have been described in various combinations, mainly with hyperparathyroidism, prolactinomas and pancreatic endocrine tumors, but none of these have been associated with acromegaly[2,3,5]

  • We describe a rare combination of acromegaly and PA due to an aldosterone-producing adenoma

Read more

Summary

Introduction

In the literature several patients with primary aldosteronism (PA) associated with endocrine and non-endocrine tumors have been reported[1,2,3]. Recovery from hypokalemia was recorded (potassium: 4.95 mmol/l) Over this period the antihypertensive therapy was reduced and she was receiving only a small dose of a Ca blocker (nitrendipine 40 mg daily). In the last three years of her regular follow-up visits the patient was found to be normokalemic and normotensive on a double antihypertensive therapy (ACE-inhibitor and Ca blocker) Her most recent visit to our unit was in June 2013. Hormonal parameters showed IGF-1 to be 20.1 nmol/l (normal range: 14–40.5), serum GH during OGTT was: 0 min 2.7 mUI/l; 60 min 1.6 mUI/l; 120 min 1.4 mUI/l (criteria for acromegaly control: basal GH

Findings
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call